Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes all‐cause mortality compared with liver transplantation (very low certainty).
N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus folinic acid (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
It is very uncertain whether surgery changes all‐cause mortality at maximal compared with radiofrequency ablation (very low certainty).
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
It is very uncertain whether external beam radiotherapy (EBRT) changes all‐cause mortality (at 1 year) compared with transarterial chemoembolisation (TACE) (very low certainty).